Pharmacogenetics of antipsychotic-induced movement disorders as a resource for better understanding Parkinson's disease modifier genes (Q28088705)

Bernard Lerer

series ordinal

2

1 reference

language of work or name

1 reference

20 February 2015

1 reference

published in

Frontiers in Neurology

1 reference

volume

6

1 reference

page(s)

27

1 reference

Epigenetic landscape of Parkinson's disease: emerging role in disease mechanisms and therapeutic modalities

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4335175

Meta-analysis of early nonmotor features and risk factors for Parkinson disease

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4335175

Genetics of Parkinson's disease

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4335175

Parkinson's Disease: Genetics and Pathogenesis

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4335175

Missing pieces in the Parkinson's disease puzzle

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4335175

Parkinson's disease: clinical features and diagnosis

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4335175

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4335175

Early development of levodopa-induced dyskinesias and response fluctuations in young-onset Parkinson's disease

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4335175

Candidate gene-based association study of antipsychotic-induced movement disorders in long-stay psychiatric patients: a prospective study

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4335175

Genomewide association study for onset age in Parkinson disease

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4335175

Parkinson's disease: mechanisms and models

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4335175

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4335175

Maladaptive plasticity in levodopa-induced dyskinesias and tardive dyskinesias: old and new insights on the effects of dopamine receptor pharmacology

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4335175

Blood-based biomarkers for Parkinson's disease

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4335175

Gray matter abnormalities in schizophrenia patients with tardive dyskinesia: a magnetic resonance imaging voxel-based morphometry study

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4335175

Perspective: Identification of genetic variants associated with dopaminergic compensatory mechanisms in early Parkinson's disease

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4335175

The Val158Met COMT polymorphism is a modifier of the age at onset in Parkinson's disease with a sexual dimorphism

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4335175

The pharmacogenetics of antipsychotic-induced adverse events

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4335175

Pharmacogenetics of antipsychotics: recent progress and methodological issues

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4335175

Nature or nurture? Determining the heritability of human striatal dopamine function: an [18F]-DOPA PET study

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4335175

Clinical aspects and management of levodopa-induced dyskinesia.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4335175

Pharmacogenetics of response to antipsychotics in patients with schizophrenia

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4335175

Genetics of Tardive Dyskinesia

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4335175

Molecular mechanisms of l-DOPA-induced dyskinesia.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4335175

l-Dopa-Induced Dyskinesia—Clinical Presentation, Genetics, and Treatment

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4335175

An introduction to dyskinesia--the clinical spectrum

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4335175

Psychopharmacological treatment of schizophrenia: What do we have, and what could we get?

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4335175

Genetics of Antipsychotic-induced Side Effects and Agranulocytosis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4335175

Pharmacogenomics of antipsychotics efficacy for schizophrenia

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4335175

Movement Disorders Induced by Antipsychotic Drugs: Implications of the CATIE Schizophrenia Trial

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4335175

Quantification of indirect pathway inhibition by the adenosine A2a antagonist SYN115 in Parkinson disease.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4335175

Molecular imaging of the dopamine transporter

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4335175

Imaging of compensatory mechanisms in Parkinson's disease.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4335175

Association of the HSPG2 gene with neuroleptic-induced tardive dyskinesia

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4335175

Pathway analysis of GWAS provides new insights into genetic susceptibility to 3 inflammatory diseases

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4335175

Genomewide association study of movement-related adverse antipsychotic effects

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4335175

Mechanisms compensating for dopamine loss in early Parkinson disease

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4335175

How do you treat motor complications in Parkinson's disease: Medicine, surgery, or both?

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4335175

Spontaneous movement disorders in antipsychotic-naive patients with first-episode psychoses: a systematic review

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4335175

Levodopa-induced dyskinesias and their management.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4335175

Neurological signs and involuntary movements in schizophrenia: intrinsic to and informative on systems pathobiology

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4335175

Pharmacogenetics in psychiatry: are we ready for widespread clinical use?

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4335175

Molecular mechanisms of L-DOPA-induced dyskinesia

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4335175

Tardive dyskinesia and new antipsychotics

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4335175

SPECT imaging of the dopaminergic system in (premotor) Parkinson's disease

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4335175

Pre-synaptic dopaminergic compensation after moderate nigrostriatal damage in non-human primates

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4335175

Levodopa-induced dyskinesias

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4335175

Tardive dyskinesia: eliminated, forgotten, or overshadowed?

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4335175

Role of hyperactive cerebellum and motor cortex in Parkinson's disease

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4335175

The mystery of motor asymmetry in Parkinson's disease

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4335175

Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4335175

Pharmacogenetics of antipsychotic therapy: pivotal research issues and the prospects for clinical implementation

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4335175

Epidemiological, clinical, and genetic characteristics of early-onset parkinsonism

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4335175

Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 1: pathophysiology and mechanisms of induction

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4335175

The 'magic' of L-dopa: why is it the gold standard Parkinson's disease therapy?

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4335175

Motor fluctuations and dyskinesias in Parkinson's disease: clinical manifestations

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4335175

Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4335175

Pathophysiology of antipsychotic drug-induced movement disorders.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4335175

Pharmacogenetics of psychotropic drug response

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4335175

Antipsychotic Drug-Induced Movement Disorders

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4335175

Carvedilol attenuates neuroleptic-induced orofacial dyskinesia: possible antioxidant mechanisms

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4335175

Dyskinesia: L-dopa-induced and tardive dyskinesia.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4335175

Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4335175

The spectrum of levodopa-induced dyskinesias

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4335175

Prevalence of spontaneous dyskinesia in schizophrenia.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4335175

Incidence and distribution of parkinsonism in Olmsted County, Minnesota, 1976-1990.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4335175

Induction of reactive oxygen species in neurons by haloperidol.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4335175

Novel antipsychotics, extrapyramidal side effects and tardive dyskinesia.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4335175

Treatment of tardive dyskinesia

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4335175

Pathogenesis, prevention, and treatment of neuroleptic-induced movement disorders.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4335175

Predicting the long-term risk of tardive dyskinesia in outpatients maintained on neuroleptic medications.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4335175

Neuroleptic-induced Parkinson's syndrome: clinical features and results of treatment with levodopa

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4335175

Compensations after lesions of central dopaminergic neurons: some clinical and basic implications

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4335175

Parkinson's disease: pathophysiology

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4335175

Gender differences in tardive dyskinesia: a critical review of the literature

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4335175

The role of apolipoprotein E polymorphisms in levodopa-induced dyskinesia

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4335175

Amantadine reduces levodopa-induced dyskinesias in parkinsonian monkeys

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4335175

2 June 2018

Neuroleptic Intolerance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4335175

Dynamic changes in striatal dopamine D2 and D3 receptor protein and mRNA in response to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) denervation in baboons

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4335175

Dopamine transporter messenger RNA in Parkinson's disease and control substantia nigra neurons

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4335175

Neurochemical Compensation After Nigrostriatal Bundle Injury in an Animal Model of Preclinical Parkinsonism

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4335175

Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4335175

Relation between brain dopamine loss and D2 dopamine receptor density in MPTP monkeys

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4335175

Tardive dyskinesia in elderly psychiatric patients: a 5-year study

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4335175

Dopamine receptor binding enhancement accompanies lesion-induced behavioral supersensitivity

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4335175

Medication-induced weight gain and dyslipidemia in patients with schizophrenia

2 June 2018

1 reference

https://api.crossref.org/works/10.3389/FNEUR.2015.00027

DPP6 as a candidate gene for neuroleptic-induced tardive dyskinesia

21 January 2018

1 reference

https://api.crossref.org/works/10.3389/FNEUR.2015.00027

Support for association of HSPG2 with tardive dyskinesia in Caucasian populations

21 January 2018

1 reference

https://api.crossref.org/works/10.3389/FNEUR.2015.00027

Pharmacogenetics of parkinsonism, rigidity, rest tremor, and bradykinesia in African-Caribbean inpatients: differences in association with dopamine and serotonin receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.3389/FNEUR.2015.00027

Further evidence for the association between 5-HT2C receptor gene polymorphisms and extrapyramidal side effects in male schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3389/FNEUR.2015.00027

Association of the RGS2 gene with extrapyramidal symptoms induced by treatment with antipsychotic medication

21 January 2018

1 reference

https://api.crossref.org/works/10.3389/FNEUR.2015.00027

Further evidence for association of the RGS2 gene with antipsychotic-induced parkinsonism: protective role of a functional polymorphism in the 3'-untranslated region

21 January 2018

1 reference

https://api.crossref.org/works/10.3389/FNEUR.2015.00027

Lack of association between antipsychotic-induced Parkinsonism or its subsymptoms and rs4606 SNP of RGS2 gene in African-Caribbeans and the possible role of the medication: the Curacao extrapyramidal syndromes study X.

21 January 2018

1 reference

https://api.crossref.org/works/10.3389/FNEUR.2015.00027

Association analysis between functional polymorphism of the rs4606 SNP in the RGS2 gene and antipsychotic-induced Parkinsonism in Japanese patients with schizophrenia: results from the Juntendo University Schizophrenia Projects (JUSP).

21 January 2018

1 reference

https://api.crossref.org/works/10.3389/FNEUR.2015.00027

Genome-wide association study of antipsychotic-induced parkinsonism severity among schizophrenia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3389/FNEUR.2015.00027

Association of the ZFPM2 gene with antipsychotic-induced parkinsonism in schizophrenia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3389/FNEUR.2015.00027

Genetics and epigenetics of Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3389/FNEUR.2015.00027

[123I]-FP/CIT SPECT imaging for distinguishing drug-induced parkinsonism from Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3389/FNEUR.2015.00027

[¹²³I]FP-CIT single photon emission computed tomography findings in drug-induced Parkinsonism.

21 January 2018

1 reference

https://api.crossref.org/works/10.3389/FNEUR.2015.00027

Clinical characteristics of neuroleptic-induced parkinsonism

21 January 2018

1 reference

https://api.crossref.org/works/10.3389/FNEUR.2015.00027

How does Parkinson's disease begin? The role of compensatory mechanisms.

21 January 2018

1 reference

https://api.crossref.org/works/10.3389/FNEUR.2015.00027

Dopamine transporter relation to dopamine turnover in Parkinson's disease: a positron emission tomography study

21 January 2018

1 reference

https://api.crossref.org/works/10.3389/FNEUR.2015.00027

The fate of striatal dopaminergic neurons in Parkinson's disease and Huntington's chorea

21 January 2018

1 reference

https://api.crossref.org/works/10.3389/FNEUR.2015.00027

Motor reserve and novel area recruitment: amplitude and spatial characteristics of compensation in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3389/FNEUR.2015.00027

Association of nicotine dependence susceptibility gene, CHRNA5, with Parkinson's disease age at onset: gene and smoking status interaction.

21 January 2018

1 reference

https://api.crossref.org/works/10.3389/FNEUR.2015.00027

Nigral dysfunction in drug-induced parkinsonism: an 18F-dopa PET study

21 January 2018

1 reference

https://api.crossref.org/works/10.3389/FNEUR.2015.00027

[123I]FP-CIT SPET imaging in drug-induced Parkinsonism.

21 January 2018

1 reference

https://api.crossref.org/works/10.3389/FNEUR.2015.00027

Clinical and [123I]FP-CIT SPET imaging follow-up in patients with drug-induced parkinsonism.

21 January 2018

1 reference

https://api.crossref.org/works/10.3389/FNEUR.2015.00027

A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa

21 January 2018

1 reference

https://api.crossref.org/works/10.3389/FNEUR.2015.00027

Sydney Multicenter Study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years

21 January 2018

1 reference

https://api.crossref.org/works/10.3389/FNEUR.2015.00027

Sex differences in clinical and genetic determinants of levodopa peak-dose dyskinesias in Parkinson disease: an exploratory study

21 January 2018

1 reference

https://api.crossref.org/works/10.3389/FNEUR.2015.00027

Dyskinesias and motor fluctuations in Parkinson's disease. A community-based study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3389/FNEUR.2015.00027

Markers of glutamatergic neurotransmission and oxidative stress associated with tardive dyskinesia

21 January 2018

1 reference

https://api.crossref.org/works/10.3389/FNEUR.2015.00027

Intravenous amantadine improves levadopa-induced dyskinesias: an acute double-blind placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3389/FNEUR.2015.00027

A controlled trial of amantadine hydrochloride and neuroleptics in the treatment of tardive dyskinesia

21 January 2018

1 reference

https://api.crossref.org/works/10.3389/FNEUR.2015.00027

Do tardive dyskinesia and L-dopa induced dyskinesia share common genetic risk factors? An exploratory study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3389/FNEUR.2015.00027

Motor complications in patients form the German Competence Network on Parkinson's disease and the DRD3 Ser9Gly polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.3389/FNEUR.2015.00027

BDNF val66met influences time to onset of levodopa induced dyskinesia in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3389/FNEUR.2015.00027

New dopaminergic neurons in Parkinson's disease striatum

21 January 2018

1 reference

https://api.crossref.org/works/10.3389/FNEUR.2015.00027

Atypical Antipsychotics and Parkinsonism

21 January 2018

1 reference

https://api.crossref.org/works/10.3389/FNEUR.2015.00027

Evidence That Early Extrapyramidal Symptoms Predict Later Tardive Dyskinesia: A Prospective Analysis of 10,000 Patients in the European Schizophrenia Outpatient Health Outcomes (SOHO) Study

21 January 2018

1 reference

https://api.crossref.org/works/10.3389/FNEUR.2015.00027

Age-specific progression of nigrostriatal dysfunction in Parkinson's disease

21 January 2018

1 reference

12 December 2020

Prospective study of tardive dyskinesia in the elderly: rates and risk factors

1 reference

12 December 2020

Evidence that early extrapyramidal symptoms predict later tardive dyskinesia: a prospective analysis of 10,000 patients in the European Schizophrenia Outpatient Health Outcomes (SOHO) study

1 reference

12 December 2020

Increased prefrontal volume in PD with levodopa-induced dyskinesias: A voxel-based morphometry study

1 reference

12 December 2020

Therapeutic implications of differential effects of new phenothiazine compounds

1 reference

12 December 2020

Alteration in RGS2 expression level is associated with changes in haloperidol induced extrapyramidal features in a mutant mouse model

1 reference

12 December 2020

Amantadine versus biperiden: a double-blind study of treatment efficacy in neuroleptic extrapyramidal movement disorders

1 reference

12 December 2020

Genome-wide association studies and systems biology: together at last

1 reference

12 December 2020

Onset and spread of dyskinesias and motor symptoms in Parkinson's disease

1 reference

12 December 2020

Drug-induced parkinsonism

1 reference

12 December 2020

A survey of drug-induced extrapyramidal reactions

1 reference

12 December 2020

1 reference

12 December 2020

Expression of glutamic acid decarboxylase mRNA in striatum and pallidum in an animal model of tardive dyskinesia

1 reference

12 December 2020

Evidence for association of the GLI2 gene with tardive dyskinesia in patients with chronic schizophrenia

1 reference

12 December 2020

L-Dopa treatment abolishes the numerical increase in striatal dopaminergic neurons in parkinsonian monkeys

1 reference

12 December 2020

In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease

1 reference

12 December 2020

1 reference

12 December 2020

Identifiers

DOI

10.3389/FNEUR.2015.00027

0 references

1 reference

PubMed publication ID

25750634

1 reference